The sweep flagged one regulatory item relevant to rheumatology today: an FDA supplemental action on Yusimry (adalimumab-aqvh), an adalimumab biosimilar. There was no new drug class, mechanism or safety signal for inflammatory arthritis in today's approvals and recalls.
Biosimilar actions matter less for what to prescribe than for cost and access: more adalimumab biosimilars on the market is downward pressure on the price of a drug most rheumatology units use heavily, and a reason to check which product your formulary and patients' insurers now prefer.
Beyond drug regulators, the guidance that actually shapes rheumatology practice — treat-to-target thresholds, tapering rules, vaccination and screening before biologics — comes from society recommendations published as documents rather than FDA actions, and none changed in today's sweep.
- FDA supplemental action on an adalimumab biosimilar (Yusimry, adalimumab-aqvh)
- No new inflammatory-arthritis drug class, mechanism or safety signal today
- Relevance is cost and formulary preference, not a change in what to prescribe
- Practice-shaping guidance for rheumatology comes from society documents, not the drug-approval sweep
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free